Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND ACE INHIBITORS: OPTIMIZATION OF CHOICE FOR TREATMENT OF CARDIOVASCULAR DISEASES

https://doi.org/10.20996/1819-6446-2010-6-1-61-67

Full Text:

Abstract

Aim. To evaluate the cardioprotective effects of ACE inhibitor, ramipril and angiotensin II receptor antagonist (ARA), valsartan at the cardiovascular continuum (CVC) stages.

Material and methods. 577 patients were examined. Patients with arterial hypertension (HT) (n=283; group 1), with metabolic syndrome (n=137; group 2), with HT associated with ischemic heart disease (n=157; group 3) were randomized into treatment subgroups A (ramipril) and B (valsartan). All patients had clinical examination, transthoracic echocardiography with remodeling indexes calculation, ambulatory blood pressure monitoring initially and after 6 months of therapy.

Results. Valsartan had priority in prevention of early cardiac remodeling (reduction in left ventricular (LV) hypertrophy and myocardial stress, improvement of functional heart parameters) at early CVC stage (HT, metabolic syndrome). On the other hand ramipril had priority at advanced stage of CVC (reduction in systolic diameter-thickness ratio, LV hypertrophy, myocardial stress and myocardial stiffness). At the advance stage of CVC valsartan treatment also resulted in significant reduction in LV hypertrophy and myocardial stress, improvement in cardiac remodeling functional parameters but had no effect on LV diameter-thickness ratio.

Conclusion. The ARA treatment is preferred at early CVC stage for better cardioprotection.

About the Authors

E. M. Khurs
Ural State Medical Academy
Russian Federation

The chair of internal disease, endocrinology and clinical pharmacology

Repina ul. 36, Ekaterinburg, 620028 



A. V. Poddubnaya
Ural State Medical Academy
Russian Federation

The chair of internal disease, endocrinology and clinical pharmacology

Repina ul. 36, Ekaterinburg, 620028 



References

1. Ощепкова Е.В. Смертность населения от сердечно-сосудистых заболеваний в Российской Федерации в 2001-2006 гг. и пути по ее снижению. Кардиология 2009;49(2):67-72.

2. Dzau V.J., Antman E.M., Black H.R. et al. The cardiovascular disease continuum validated: clinical evidence ofimproved patient outcomes: partI: Pathophysiology and clinicaltrial evidence (risk factors through stable coronary artery disease). Circulation 2006;114(25):2850–70.

3. Konstam M.A., Rousseau M.F., Kronenberg M.W. et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression ofleft ventricular dysfunction in patients with heart failure. Circulation 1992;86(2):431–8.

4. Konstam M.A., Kronenberg M.W., Rousseau M.F. et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation 1993;88(5 Pt 1):2277-83.

5. Greenberg B., Quinones M., Kolpillai C. et al. Effect oflong-term enalapril on cardiac structure and function in patients with left ventricular dysfunction. Circulation 1995;91(10):2573-81.

6. Pfeffer M.A., Braunwald E., Moye L.A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327(10):669-77.

7. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heartfailure:results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316(23):1429-35.

8. TheAcute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect oframipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342(8875):821-8.

9. Baker K.M., Johns D.W., Vaughan E.D. Jr. et al. Antihypertensive effects of angiotensin blockade: saralasin versus captopril. Clin Exp Hypertens 1980;2(6):947-54.

10. MatcharD.B., McCroryD.C., Orlando L.A. et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin IIreceptor blockers fortreating essential hypertension. Ann Intern Med 2008;148(1):16-29.

11. Pitt B., Poole-Wilson P.A., Segal R. et al. on behalf of the ELITE II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heartfailure:randomised trial — the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355(9215):1582-7.

12. Dickstein K., Kjekshus J.; OPTIMAAL Steering Committee ofthe OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity high–risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360(9335):752-60.

13. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547-59.

14. Диагностика и лечение артериальной гипертензии. В: Оганов Р.Г., редактор.Национальные клинические рекомендации. М.: Силицея-Полиграф; 2009; 292-332.

15. Диагностика и лечение метаболического синдрома. В: Оганов Р.Г., редактор.Национальные клинические рекомендации. М.: Силицея-Полиграф; 2009; 106-148.

16. Диагностика и лечение стабильной стенокардии. В: Оганов Р.Г., редактор.Национальные клинические рекомендации. М.: Силицея-Полиграф; 2009; 332-386.

17. Lang R.M., Bierig M., Devereux R.B. et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006;7(2):79-108.

18. DevereuxR.B.,ReichekN. Echocardiographic determination ofleft ventricular mass in man.Anatomic validation of the method. Circulation 1977;55(4):613-8.

19. GanauA.,Devereux R.B., Roman M.J. et al. Patterns ofleft ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992;19(7):1550-8.

20. Braunwald Е. ACE inhibitors - a cornerstone of the treatment of heart failure. N Engl J Med 1991;325(5):351-3.

21. Cuocolo A., Storto G., Izzo R. et al. Effects of valsartan on left ventricular diastolic function in patients with mild or moderate essential hypertension: comparison with enalapril. J Hypertens 1999;17(12 Pt 1):1759-66


For citation:


Khurs E.M., Poddubnaya A.V. ANGIOTENSIN II RECEPTOR ANTAGONISTS AND ACE INHIBITORS: OPTIMIZATION OF CHOICE FOR TREATMENT OF CARDIOVASCULAR DISEASES. Rational Pharmacotherapy in Cardiology. 2010;6(1):61-67. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-1-61-67

Views: 313


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)